Clinical comprehensive evaluation of recombinant Mycobacterium tuberculosis fusion protein
- VernacularTitle:重组结核杆菌融合蛋白的临床综合评价
- Author:
Xiaofeng NI
1
;
Sha DIAO
1
;
Siyi HE
1
;
Xuefeng JIAO
1
;
Xiao CHENG
1
;
Zhe CHEN
1
;
Zheng LIU
1
;
Linan ZENG
1
;
Deying KANG
2
;
Bin WU
3
;
Chaomin WAN
1
,
4
;
Binwu YING
5
;
Hui ZHANG
6
;
Rongsheng ZHAO
7
;
Liyan MIAO
8
;
Zhuo WANG
9
;
Xiaoyu LI
10
;
Maobai LIU
11
;
Benzhi CAI
12
;
Feng QIU
13
;
Feng SUN
14
;
Naihui CHU
15
;
Minggui LIN
16
;
Wei SHA
17
;
Lingli ZHANG
1
Author Information
1. Dept. of Pharmacy/Evidence-Based Pharmacy Center/NMPA Key Laboratory for Technical Research on Drug Products in vitro and in vivo Correlation/Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education，West China Second University Hospital，Sichuan University，Chengdu 610041，China
2. Evidence-based Medicine Center，West China Hospital，Sichuan University，Chengdu 610041，China
3. Dept. of Pharmacy，Renji Hospital，School of Medicine，Shanghai Jiaotong University，Shanghai 200127，China
4. Dept. of Pediatrics，West China Second University Δ 基金项目 四川省科技计划项目 （重点研发项目 ）（No. Hospital，Sichuan University，Chengdu 610041，China
5. Dept. of Laboratory Medicine，West China Hospital，电话：028-85503205。E-mail：nixiaofenger@163.com Sichuan University，Chengdu 610041，China
6. Dept. of # 通信作者主任药师，博士生导师，博士。研究方向：循证药物决 策与管理、循证临床药学研究与实践 。电话：028-85503205。E-mail： Infection Management，West China Hospital，Sichuan zhanglingli@scu.edu.cn University，Chengdu 610041，China
7. Dept. of 中国药房 2023年第34卷第4期 China Pharmacy 2023 Vol. 34 No. 4 · 391 · Pharmacy，Peking University Third Hospital，Beijing 100191，China
8. Dept. of Pharmacy，the First Affiliated Hospital of Soochow University，Suzhou 215006，China
9. Dept. of Pharmacy，Changhai Hospital，Naval Medical University，Shanghai 200433，China
10. Dept. of Pharmacy，Zhongshan Hospital，Fudan University，Shanghai 200032，China
11. Dept. of Pharmacy，Fujian Medical University Union Hospital，Fuzhou 350001，China
12. Dept. of Pharmacy，the Second Affiliated Hospital，Harbin Medical University，Harbin 150086，China
13. Dept. of Pharmacy，the First Affiliated Hospital of Chongqing Medical University，Chongqing 400016，China
14. International Research Center for Medicinal Administration，Peking University，Beijing 100191，China
15. Dept. of Tuberculosis，Beijing Chest Hospital，Capital Medical University，Beijing 101149，China
16. Dept. of Infection，Beijing Tsinghua Changgung Hospital，Tsinghua University，Beijing 102218，China
17. Dept. of Tuberculosis，Shanghai Pulmonary Hospital Affiliated to Tongji University，Shanghai 200433，China
- Publication Type:Journal Article
- Keywords:
recombinant Mycobacterium tuberculosis fusion protein;
purified protein derivative of tuberculin;
tuberculosis
- From:
China Pharmacy
2023;34(4):391-396
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the effectiveness， safety， economy， innovation， suitability and accessibility of recombinant Mycobacterium tuberculosis fusion protein （EC）， and to provide evidence for selecting skin detection methods for tuberculosis infection diagnosis and auxiliary diagnosis of tuberculosis. METHODS The effectiveness and safety of EC compared with purified protein derivative of tuberculin （TB-PPD） were analyzed by the method of systematic review. Cost minimization analysis， cost-effectiveness analysis and cost-utility analysis were used to evaluate the short-term economy of EC compared with TB-PPD， and cost-utility analysis was used to evaluate the long-term economy. The evaluation dimensions of innovation， suitability and accessibility were determined by systematic review and improved Delphi expert consultation， and the comprehensive score of EC and TB-PPD in each dimension were calculated by the weight of each indicator. RESULTS The scores of effectiveness， safety， economy， innovation and suitability of EC were all higher than those of TB-PPD. The affordability scores of the two drugs were consistent， while the availability score of EC was lower than those of TB-PPD. After considering dimensions and index weight， the scores of effectiveness， safety， economy， innovation， suitability， accessibility and the comprehensive score of EC were all higher than those of TB-PPD. CONCLUSIONS Compared with TB-PPD， EC performs better in all dimensions of effectiveness， safety， economy， innovation， suitability and accessibility. However， it is worth noting that EC should further improve its availability in the dimension of accessibility.
